sirolimus and Syndrome

sirolimus has been researched along with Syndrome* in 31 studies

Reviews

5 review(s) available for sirolimus and Syndrome

ArticleYear
Progeria syndromes and ageing: what is the connection?
    Nature reviews. Molecular cell biology, 2010, Volume: 11, Issue:8

    One of the many debated topics in ageing research is whether progeroid syndromes are really accelerated forms of human ageing. The answer requires a better understanding of the normal ageing process and the molecular pathology underlying these rare diseases. Exciting recent findings regarding a severe human progeria, Hutchinson-Gilford progeria syndrome, have implicated molecular changes that are also linked to normal ageing, such as genome instability, telomere attrition, premature senescence and defective stem cell homeostasis in disease development. These observations, coupled with genetic studies of longevity, lead to a hypothesis whereby progeria syndromes accelerate a subset of the pathological changes that together drive the normal ageing process.

    Topics: Aging; Animals; Biological Evolution; DNA Damage; DNA Repair; Humans; Lamin Type A; Longevity; Mesenchymal Stem Cells; Models, Biological; Progeria; Signal Transduction; Sirolimus; Syndrome

2010
[Technical evolution of the stent].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:4

    Percutaneous coronary intervention has been hampered by restenosis since its inception. Many research projects including the use of various devices and systemic drug administration have shown disappointing results. Recently, the advent of drug-eluting stents has reduced incidence of restenosis compared with bare metal stents. This article provides an overview of the developments of drug-eluting stents, their clinical impact on the treatment of acute coronary syndrome, and their future perspectives.

    Topics: Angina, Unstable; Animals; Clinical Trials as Topic; Coronary Restenosis; Drug Delivery Systems; Humans; Myocardial Infarction; Paclitaxel; Prognosis; Sirolimus; Stents; Syndrome

2006
Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome.
    Diabetes & vascular disease research, 2005, Volume: 2, Issue:3

    Diabetes mellitus has reached epidemic proportions worldwide. Patients with diabetes are at increased risk for acute coronary syndromes, and these syndromes lead to frequent morbidity and cardiovascular mortality. Emerging adjunctive pharmacological strategies coupled with the drug-eluting stent platform have resulted in improved adverse event rates for this high-risk group. This review will concentrate on the historical data associated with acute coronary syndromes in diabetes mellitus, focusing on revascularisation, drug-eluting stents and antiplatelet therapies.

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Diabetes Complications; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Sirolimus; Stents; Syndrome

2005
[New devices for coronary interventions in patients with acute coronary syndrome].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Feb-10, Volume: 93, Issue:2

    Topics: Angina, Unstable; Atherectomy, Coronary; Catheterization; Coronary Artery Disease; Coronary Thrombosis; Death, Sudden, Cardiac; Humans; Immunosuppressive Agents; Myocardial Infarction; Sirolimus; Stents; Syndrome

2004
Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
    Journal of the American College of Cardiology, 2003, Jun-04, Volume: 41, Issue:11

    This study evaluated the early outcomes of patients with acute coronary syndromes (ACS) treated with sirolimus-eluting stents (SES).. The safety of SES implantation in patients with a high risk for early thrombotic complications is currently unknown.. Sirolimus-eluting stents have been utilized as the device of choice for all percutaneous procedures in our institution, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. After four months of enrollment, 198 patients with ACS had been treated exclusively with SES (64% of those treated in the period) and were compared with a control group composed of 301 consecutive patients treated with bare stents in the same time period immediately before this study. The incidence of major adverse cardiac events (MACE) during the first month was evaluated (death, nonfatal myocardial infarction [MI], or re-intervention).. Compared with control patients, patients treated with SES had more primary angioplasty (95% vs. 77%; p < 0.01), more bifurcation stenting (13% vs. 5%; p < 0.01), less previous MI (28% vs. 45%; p < 0.01), and less glycoprotein IIb/IIIa inhibitor utilization (27% vs. 42%; p < 0.01). The 30-day MACE rate was similar between both groups (SES 6.1% vs. control patients 6.6%; p = 0.8), with most complications occurring during the first week. Stent thrombosis occurred in 0.5% of SES patients and in 1.7% of control patients (p = 0.4). In multivariate analysis, SES utilization did not influence the incidence of MACE (odds ratio 1.0 [95% confidence interval: 0.4 to 2.2]; p = 0.97).. Sirolimus-eluting stent implantation for patients with ACS is safe, with early outcomes comparable with bare metal stents.

    Topics: Acute Disease; Aged; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Combined Modality Therapy; Coronary Disease; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Netherlands; Postoperative Complications; Predictive Value of Tests; Risk Factors; Sirolimus; Stents; Syndrome; Time Factors; Treatment Outcome

2003

Trials

3 trial(s) available for sirolimus and Syndrome

ArticleYear
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Nature, 2018, Volume: 558, Issue:7711

    CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome) is a genetic disorder that results from somatic, mosaic gain-of-function mutations of the PIK3CA gene, and belongs to the spectrum of PIK3CA-related overgrowth syndromes (PROS). This rare condition has no specific treatment and a poor survival rate. Here, we describe a postnatal mouse model of PROS/CLOVES that partially recapitulates the human disease, and demonstrate the efficacy of BYL719, an inhibitor of PIK3CA, in preventing and improving organ dysfunction. On the basis of these results, we used BYL719 to treat nineteen patients with PROS. The drug improved the disease symptoms in all patients. Previously intractable vascular tumours became smaller, congestive heart failure was improved, hemihypertrophy was reduced, and scoliosis was attenuated. The treatment was not associated with any substantial side effects. In conclusion, this study provides the first direct evidence supporting PIK3CA inhibition as a promising therapeutic strategy in patients with PROS.

    Topics: Adult; Animals; Child; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Female; Heart Failure; HeLa Cells; Humans; Lipoma; Male; Mice; Molecular Targeted Therapy; Musculoskeletal Abnormalities; Nevus; Phenotype; Scoliosis; Sirolimus; Syndrome; Thiazoles; Vascular Malformations; Vascular Neoplasms

2018
Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2006, Volume: 6, Issue:1

    Everolimus is a proliferation signal inhibitor with immunosuppressive activity that may reduce the rate of progression of chronic rejection, bronchiolitis obliterans syndrome (BOS), after lung transplantation. In a randomized, double-blind clinical trial, 213 BOS-free maintenance patients received everolimus (3 mg/day) or azathioprine (AZA, 1-3 mg/kg/day) in combination with cyclosporine and corticosteroids. The prospectively defined primary endpoint was the incidence of efficacy failure (decline in FEV1 >15%[deltaFEV1 >15%], graft loss, death or loss to follow-up) at 12 months. Incidence of efficacy failure at 12 months was significantly lower in the everolimus group than AZA (21.8% vs. 33.9%; p = 0.046); at 24 months, rates of efficacy failure became similar between the groups. At 12 months, the everolimus group had significantly reduced incidences of deltaFEV1 >15%, deltaFEV1 >15% with BOS, and acute rejection. At 24 months, only incidence of acute rejection remained significantly less in the everolimus group. Treatment discontinuations (particularly due to adverse events), serious adverse events and high serum creatinine values were more common with everolimus. For the first time, a drug has demonstrated significant slowing of loss in lung function, suggesting that patients kept on prolonged maintenance treatment with everolimus may benefit from replacing AZA with everolimus 3 months after lung transplantation.

    Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Bronchiolitis Obliterans; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Everolimus; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lung; Lung Transplantation; Male; Middle Aged; Sirolimus; Syndrome

2006
Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
    Transplantation, 2006, Feb-15, Volume: 81, Issue:3

    Bronchiolitis obliterans syndrome (BOS) is the major problem after lung and heart-lung transplantation (LTx/HLTx). Sirolimus (Sir) and Mycophenolate (MMF) showed a promising efficacy in the treatment of BOS in animal models. The first clinical experience in converting LTx/HLTx-recipients with BOS from calcineurin inhibitor-(CNI)-based immunosuppression to a Sir-MMF based immunosuppression is reported herein.. Six LTx- and five HLTx-recipients (eight men; 0.9 to 8 years after transplantation) with CNI-based immunosuppression (plus MMF) in whom BOS was diagnosed were included in the study. Mean patient age was 37+/-13 years (range 17-62 years). Sir was started with 6 mg and continued adjusted to according target trough levels (8-14 ng/ml). Subsequently, the CNIs were tapered down and finally stopped. Follow up included self determined pulmonary function tests, microbiological screening, chest radiographs, and laboratory studies. Two acute rejection episodes occurred during the study period. The incidence of infection was 2.2+/-1.3 infections/patient-year after conversion. Mean FEV1 decreased after a mean follow up of 14.8+/-1.4 months: from 2.1+/-0.7 l prior conversion to 1.3+/-0.6l after conversion (P=0.03). However, graft function remained stable in three patients and progression of BOS slowed down in three patients. Overall, 2 of 10 patients died due to ongoing BOS while awaiting retransplantation. After BOS was diagnosed, conversion to MMF and Sir stabilized graft function only in some of the converted patients. Therefore, earlier administration of Sir-based immunosuppression might be a more promising approach. Whether conversion to CNI-free immunosuppression can actually ameliorate the extent or progression of BOS has to be investigated in randomized trials.

    Topics: Adolescent; Adult; Bronchiolitis Obliterans; Calcineurin Inhibitors; Disease Progression; Female; Graft Rejection; Heart-Lung Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney; Lung Transplantation; Male; Middle Aged; Mycophenolic Acid; Sirolimus; Syndrome

2006

Other Studies

23 other study(ies) available for sirolimus and Syndrome

ArticleYear
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.
    Journal of medicinal chemistry, 2023, 07-13, Volume: 66, Issue:13

    The allosteric inhibitor of the mechanistic target of rapamycin (mTOR) everolimus reduces seizures in tuberous sclerosis complex (TSC) patients through partial inhibition of mTOR functions. Due to its limited brain permeability, we sought to develop a catalytic mTOR inhibitor optimized for central nervous system (CNS) indications. We recently reported an mTOR inhibitor (

    Topics: Adenosine Triphosphate; Animals; Brain; Central Nervous System; Mice; MTOR Inhibitors; Sirolimus; Syndrome; TOR Serine-Threonine Kinases

2023
Sirolimus for management of GI bleeding in blue rubber bleb nevus syndrome: A case series.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:11

    Blue rubber bleb nevus syndrome (BRBNS) commonly presents with anemia from bleeding gastrointestinal (GI) vascular malformations. Management is highly variable, as no consensus guidelines for medical treatment currently exist. Sirolimus has been used in BRBNS to decrease GI bleeding and seems well tolerated, though questions remain regarding dosing, duration of therapy, and adverse effects. Here, we report our single-center experience of four pediatric patients with BRBNS who were successfully treated with sirolimus and review the existing literature regarding sirolimus for treatment of GI bleeding in BRBNS. Further prospective studies are needed to establish optimal dosage, drug monitoring, and duration.

    Topics: Child; Gastrointestinal Neoplasms; Humans; Nevus, Blue; Sirolimus; Skin Neoplasms; Syndrome

2022
Effective sirolimus treatment of 2 COPA syndrome patients.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:2

    Topics: Humans; Mutation, Missense; Sirolimus; Syndrome

2021
Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available.. To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome.. This case series focused on 4 children with treatment-refractory Olmsted syndrome. These children received treatments (initiated in 2017 and 2018) at the outpatient dermatology clinic at the Children's Hospital of Wisconsin in Milwaukee, Wisconsin; Children's National Hospital in Washington, DC; and Hospital Infantil Pequeno Príncipe, Curitiba in Paraná, Brazil.. Immunohistochemical analyses for mTOR and EGFR activation were performed on skin biopsy specimens from 2 patients. Oral sirolimus was administered to these 2 patients at a dosage of 0.8 mg/m2 twice daily, titrated to a goal trough whole-blood concentration of 10 to 15 ng/mL. Erlotinib was administered to all 4 patients at a dosage of 2 mg/kg/d.. Clinical responses were assessed with visual analog scales for pruritus and pain and/or the Children's Dermatology Life Quality Index. Adverse effects were monitored throughout treatment.. Four patients (mean [SD] age, 7 [6] years; 2 boys and 2 girls) were analyzed. Lesional skin immunostaining showed increased phosphorylated ribosomal protein S6 (RPS6) and phosphorylated EGFR staining in the epidermis, indicating enhanced mTOR and EGFR signaling activation. Patients 1 and 2 were initially treated with sirolimus, displaying substantial clinical improvement in erythema and periorificial hyperkeratosis afterward. When switched to erlotinib, these patients showed substantial palmoplantar keratoderma (PPK) improvement. Patients 3 and 4 were treated with erlotinib only and later showed rapid and near complete resolution of PPK and substantial improvement in Children's Dermatology Life Quality Index scores. All 4 patients had sustained improvements in pruritus and pain. No severe adverse effects were reported.. This study's findings suggest that the EGFR-mTOR cascade may play a substantial role in the pathophysiological process of Olmsted syndrome and may serve as a major therapeutic target. Oral sirolimus and erlotinib may be a promising, life-altering treatment for pediatric patients with Olmsted syndrome.

    Topics: Adolescent; Brazil; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunosuppressive Agents; Infant; Keratoderma, Palmoplantar; Male; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases; Treatment Outcome

2020
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia Syndrome Treated With Sirolimus.
    Annals of internal medicine, 2018, 08-07, Volume: 169, Issue:3

    Topics: Antibiotics, Antineoplastic; Carcinoid Tumor; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neuroendocrine Cells; Sirolimus; Syndrome

2018
Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.
    Human molecular genetics, 2017, 12-01, Volume: 26, Issue:23

    Mitochondrial disorders affecting oxidative phosphorylation (OxPhos) are caused by mutations in both the nuclear and mitochondrial genomes. One promising candidate for treatment is the drug rapamycin, which has been shown to extend lifespan in multiple animal models, and which was previously shown to ameliorate mitochondrial disease in a knock-out mouse model lacking a nuclear-encoded gene specifying an OxPhos structural subunit (Ndufs4). In that model, relatively high-dose intraperitoneal rapamycin extended lifespan and improved markers of neurological disease, via an unknown mechanism. Here, we administered low-dose oral rapamycin to a knock-in (KI) mouse model of authentic mtDNA disease, specifically, progressive mtDNA depletion syndrome, resulting from a mutation in the mitochondrial nucleotide salvage enzyme thymidine kinase 2 (TK2). Importantly, low-dose oral rapamycin was sufficient to extend Tk2KI/KI mouse lifespan significantly, and did so in the absence of detectable improvements in mitochondrial dysfunction. We found no evidence that rapamycin increased survival by acting through canonical pathways, including mitochondrial autophagy. However, transcriptomics and metabolomics analyses uncovered systemic metabolic changes pointing to a potential 'rapamycin metabolic signature.' These changes also implied that rapamycin may have enabled the Tk2KI/KI mice to utilize alternative energy reserves, and possibly triggered indirect signaling events that modified mortality through developmental reprogramming. From a therapeutic standpoint, our results support the possibility that low-dose rapamycin, while not targeting the underlying mtDNA defect, could represent a crucial therapy for the treatment of mtDNA-driven, and some nuclear DNA-driven, mitochondrial diseases.

    Topics: Animals; Autophagy; Disease Models, Animal; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport Complex I; Female; Gene Knock-In Techniques; Male; Mice; Mitochondria; Mitochondrial Diseases; Mutation; Oxidative Phosphorylation; Signal Transduction; Sirolimus; Syndrome; Thymidine Kinase

2017
Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
    The Annals of thoracic surgery, 2014, Volume: 97, Issue:1

    Sirolimus (SIR) has been shown to stabilize the lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, there is no long-term data on the prophylactic use of SIR in lung transplant recipients. This retrospective study examines the effects of SIR in the prevention of BOS.. From 1999 to 2009, 24 lung transplant recipients whose maintenance immunosuppression regimen consisted of tacrolimus (Tac), mycophenolate mofetil (MMF) or azathioprine (AZA), and prednisone (Pred), were switched to Tac, SIR, and Pred at 1 year after transplantation. From these 24 patients, 5 developed side effects that necessitated the cessation of SIR within 1 year, while 19 patients tolerated long-term use of SIR. The clinical outcomes of these 19 patients (SIR group) were compared with 22 lung transplant recipients whose immunosuppression regimen consisted of Tac, MMF or AZA, and Pred from the time of transplant (MMF group). Survival rates and freedom from BOS were calculated by the Kaplan-Meier method.. The SIR group had a lower incidence of BOS and viral infection (p = 0.05), and higher survival rates (p = 0.004). The SIR group had lower levels of Tac and received less Pred. The incidences of acute rejection, carcinoma, hypertension, and diabetes were similar between both groups.. Results from this study suggest that conversion to SIR 1 year after lung transplantation improves survival and decreases the development of BOS. Randomized studies with higher number of patients are needed to determine the prophylactic efficacy of sirolimus in preventing the development of BOS.

    Topics: Adult; Bronchiolitis Obliterans; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Primary Prevention; Retrospective Studies; Sirolimus; Survival Rate; Syndrome; Treatment Outcome

2014
Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome.
    Transplant international : official journal of the European Society for Organ Transplantation, 2014, Volume: 27, Issue:9

    Topics: Blindness, Cortical; Blood Group Incompatibility; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Confusion; Drug Substitution; Drug Therapy, Combination; Emergencies; Everolimus; Graft Rejection; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photopheresis; Plasmapheresis; Sirolimus; Syndrome; Tacrolimus

2014
Kounis syndrome manifesting as coronary aneurysm and very late coronary stent thrombosis.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Angioscopy; Biopsy; Cardiovascular Agents; Coronary Aneurysm; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Myocardial Infarction; Neointima; Percutaneous Coronary Intervention; Predictive Value of Tests; Prosthesis Design; Risk Factors; Sirolimus; Syndrome; Thrombectomy; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional

2014
Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival.
    Cancer research, 2012, Feb-01, Volume: 72, Issue:3

    Anorexia-cachexia syndrome (ACS) is a major determinant of cancer-related death that causes progressive body weight loss due to depletion of skeletal muscle mass and body fat. Here, we report the development of a novel preclinical murine model of ACS in which lymphomas harbor elevated Myc and activated mTOR signaling. The ACS phenotype in this model correlated with deregulated expression of a number of cytokines, including elevated levels of interleukin-10 which was under the direct translational control of mTOR. Notably, pharmacologic intervention to impair protein synthesis restored cytokine production to near-normal levels, delayed ACS progression, and extended host survival. Together, our findings suggest a new paradigm to treat ACS by strategies which target protein synthesis to block the production of procachexic factors.

    Topics: Animals; Anorexia; Antineoplastic Agents; Body Weight; Cachexia; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Female; Harringtonines; Homoharringtonine; Humans; Interleukin-10; Kaplan-Meier Estimate; Lymphoma; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Protein Biosynthesis; Proto-Oncogene Proteins c-myc; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases

2012
The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, Dec-01, Volume: 76, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Agents; Drug-Eluting Stents; Everolimus; Humans; Hypersensitivity; Myocardial Infarction; Paclitaxel; Prosthesis Design; Sirolimus; Syndrome; Thrombosis; Treatment Outcome

2010
Letter by Kounis et al regarding article, "sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy".
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:10

    Topics: Aged; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Hypersensitivity; Male; Manganese; Metals; Sirolimus; Syndrome

2008
Epstein Barr virus induced lymphoma in a child with IPEX syndrome.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:5

    IPEX syndrome (immune deficiency, polyendocrinopathy, enteropathy, X-linked) is a disorder or regulatory T cell (Treg) function which can result in early death due to infection or complications related to autoimmunity. Therapeutic options for these patients can include allogeneic stem cell transplantation (SCT) or the use of immunosuppressive regimens to control the manifestations of autoimmunity. We report a patient with IPEX syndrome who was managed with rapamycin and subsequently developed EBV induced lymphoma.

    Topics: Child; Epstein-Barr Virus Infections; Genetic Diseases, X-Linked; Herpesvirus 4, Human; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Lymphoma; Male; Polyendocrinopathies, Autoimmune; Protein-Losing Enteropathies; Sirolimus; Syndrome

2008
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Journal of the National Cancer Institute, 2008, Jan-16, Volume: 100, Issue:2

    Patients with Birt-Hogg-Dubé (BHD) syndrome harbor germline mutations in the BHD tumor suppressor gene that are associated with an increased risk for kidney cancer. BHD encodes folliculin, a protein that may interact with the energy- and nutrient-sensing 5'-AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) signaling pathways.. We used recombineering methods to generate mice with a conditional BHD allele and introduced the cadherin 16 (KSP)-Cre transgene to target BHD inactivation to the kidney. Kidney cell proliferation was measured by BrdU incorporation and phospho-histone H3 staining. Kidney weight data were analyzed with Wilcoxon's rank-sum, Student's t, and Welch's t tests. Hematoxylin and eosin staining and immunoblot analysis and immunohistochemistry of cell cycle and signaling proteins were performed on mouse kidney cells and tissues. BHD knockout mice and kidney cells isolated from BHD knockout and control mice were treated with the mTOR inhibitor rapamycin. Mouse survival was evaluated by Kaplan-Meier analyses. All statistical tests were two-sided.. BHD knockout mice developed enlarged polycystic kidneys and died from renal failure by 3 weeks of age. Targeted BHD knockout led to the activation of Raf-extracellular signal-regulated protein kinase (Erk)1/2 and Akt-mTOR pathways in the kidneys and increased expression of cell cycle proteins and cell proliferation. Rapamycin-treated BHD knockout mice had smaller kidneys than buffer-treated BHD knockout mice had (n = 4-6 mice per group, relative kidney/body weight ratios, mean = 4.64% vs 12.2%, difference = 7.6%, 95% confidence interval = 5.2% to 10.0%; P < .001) and longer median survival time (n = 4-5 mice per group, 41.5 vs 23 days; P = .0065 ).. Homozygous loss of BHD may initiate renal tumorigenesis in the mouse. The conditional BHD knockout mouse may be a useful research model for dissecting multistep kidney carcinogenesis, and rapamycin may be considered as a potential treatment for Birt-Hogg-Dubé syndrome.

    Topics: Animals; Antibiotics, Antineoplastic; Blotting, Southern; Cell Proliferation; Disease Models, Animal; Estrone; Fluorescent Antibody Technique; Gene Silencing; Genotype; Germ-Line Mutation; Immunoblotting; Immunohistochemistry; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Polycystic Kidney Diseases; Protein Kinases; Proto-Oncogene Proteins; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins

2008
Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2007, Volume: 7, Issue:2

    Little is known about the effects of immunosuppression on patients with hereditary nonpolyposis colorectal cancer (HNPCC). We describe a kidney transplant recipient with unrecognized Muir-Torre syndrome in whom the administration of a tacrolimus-based regimen led to the eruption of multiple sebaceous tumors. The patient was later found to harbor an MSH2 mutation. Switching to a sirolimus-based regimen resulted in arrest of the disease. When the patient was switched back to tacrolimus, new facial lesions rapidly appeared. Switching again to sirolimus resulted again in halting the appearance of new lesions. This finding is in line with the known antiangiogenic activity of sirolimus and reports on the regression of cutaneous Kaposi's sarcoma in kidney transplant recipients switched from another immunosuppressive regimen to sirolimus. Further studies on the potential use of sirolimus for the treatment of de novo tumors in immunosuppressed kidney transplant recipients with HNPCC are warranted.

    Topics: Adenoma; Colorectal Neoplasms, Hereditary Nonpolyposis; Disease Progression; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mutation; MutS Homolog 2 Protein; Sebaceous Gland Neoplasms; Sirolimus; Syndrome; Tacrolimus

2007
Posterior reversible encephalopathy syndrome due to sirolimus.
    Bone marrow transplantation, 2007, Volume: 39, Issue:10

    Topics: Adult; Brain Diseases; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Peripheral Blood Stem Cell Transplantation; Sirolimus; Syndrome

2007
Comparison of bare metal stents versus drug-eluting stents on clinical decision making in patients with previous percutaneous coronary intervention admitted for suspected acute coronary syndrome.
    The American journal of cardiology, 2006, Aug-01, Volume: 98, Issue:3

    To determine whether the decreased rate of restenosis observed with drug-eluting stents (DES) has changed the treatment of patients with recurrent symptoms after stent placement, we compared patients hospitalized with presumed cardiac symptoms within 1 year after placement of either a DES or a bare metal stent (BMS). In this retrospective, single-center study, cases were identified from consecutive patients who received a DES from March 2003 to July 2004 or a BMS from August 2001 to June 2002. No differences were noted in the rate of hospitalization, hospitalization for presumed cardiac symptoms, use of coronary angiography in patients hospitalized for presumed cardiac symptoms, or average interval to hospitalization. In contrast, restenosis and the need for additional revascularization procedures were higher in the BMS group. The primary indication for additional revascularization was restenosis in the BMS group and progression of coronary artery disease in the DES group. In the DES group, the need for revascularization was significantly higher in patients with multi- versus single-vessel coronary artery disease (26% vs 7%, p < 0.05). In conclusion, the rate of hospitalization and use of coronary angiography in patients with recurrent symptoms were similar in patients who received a BMS or DES, despite the decreased rates of restenosis and additional revascularization procedures observed with DESs.

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Decision Making; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Metals; Middle Aged; Retrospective Studies; Sirolimus; Stents; Syndrome; Treatment Outcome

2006
Calcineurin-inhibitor induced pain syndrome after organ transplantation.
    Kidney international, 2006, Volume: 70, Issue:7

    Topics: Adult; Bone and Bones; Calcineurin Inhibitors; Cyclosporins; Everolimus; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Magnetic Resonance Imaging; Male; Middle Aged; Osteoporosis; Pain; Postoperative Period; Radiography; Radionuclide Imaging; Sirolimus; Syndrome; Tacrolimus; Time Factors

2006
Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry.
    American heart journal, 2006, Volume: 152, Issue:6

    Drug-eluting coronary stents are the most recent "breakthrough" technology in interventional cardiology. Whereas risk factors influencing restenosis and need for target vessel revascularization are well known, risk factors for dying or developing a myocardial infarction (MI) after drug-eluting coronary stent implantation need to be evaluated yet.. We evaluated data from the German Cypher Stent Registry.. From April 2002 to December 2004, 7445 patients at 122 hospitals, who received at least one sirolimus-eluting stent during percutaneous coronary intervention, were included. Complete follow-up at a median of 6.6 months (quartiles 6.1-8.1 months) was available in 6755 patients (91%). Death occurred in 1.8% (120/6755) of patients, nonfatal MI in 2.3% (156/6635), and death or MI in 4.1% (276/6755) of patients. Independent predictors of death or MI were initial presentation with ST-elevation MI or non-ST-elevation MI (OR [odds ratio] 2.21, 95% CI 1.66-2.95, P < .0001), cardiogenic shock (OR 3.05, 95% CI 1.67-5.55, P = .0003), renal insufficiency (OR 1.74, 95% CI 1.24-2.44, P = .0017), reduced left ventricular function (OR 1.74, 95% CI 1.21-2.50, P = .0027), age (per decade) (OR 1.19, 95% CI 1.05-1.36, P = .0058), diabetes mellitus (OR 1.39, 95% CI 1.05-1.84, P = .0183), 3-vessel disease (OR 1.32, 95% CI 0.99-1.77, P = .043), and prior MI (OR 1.35, 95% CI 1.01-1.80, P = .0468), whereas interventional and lesion characteristics showed no significant association.. These results demonstrate that the most powerful predictors of death or MI after sirolimus-eluting stent implantation during percutaneous coronary intervention are presentation with an acute coronary syndrome, impaired left ventricular ejection fraction, and conventional risk factors for coronary heart disease. Interventional and lesion characteristics do not play a major role.

    Topics: Acute Disease; Aged; Coronary Disease; Coronary Stenosis; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Registries; Risk Factors; Sirolimus; Stents; Stroke Volume; Syndrome

2006
Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).
    The Journal of pediatrics, 2005, Volume: 147, Issue:2

    IPEX (immune-dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome is an autoimmune disorder with an often lethal outcome in spite of immunosuppressive therapy. We report the successful use of sirolimus in 3 patients with IPEX. The efficacy of sirolimus is probably due to its different mode of action compared to calcineurin-dependent agents.

    Topics: Child; Humans; Immunosuppressive Agents; Male; Polyendocrinopathies, Autoimmune; Sirolimus; Syndrome

2005
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state.
    Transplantation, 2005, Nov-15, Volume: 80, Issue:9

    The responsibility of sirolimus (SRL) for postrenal transplant anemia has never been proven, because SRL is usually combined with myelotoxic drugs, and because of the high incidence of anemia in the posttransplant period.. We retrospectively analyzed anemia in 46 renal transplant recipients, who had been switched from calcineurin inhibitors to SRL for biopsy-proven chronic allograft nephropathy.. The mean decrease in hemoglobin (Hb) after SRL introduction was 2.8 g/dl. The 24 patients, whose Hb fell by >or=2 g/dl, displayed microcytic aregenerative anemia with low serum iron despite high ferritinemia, consistent with anemia of chronic inflammatory states. Fibrinogen and CRP levels increased in these patients after sirolimus introduction. We subsequently focused our study on eight patients without confounding factors of anemia. Anemia improved in all eight after SRL withdrawal. IL6 and TNFalpha at the nadir of anemia were significantly higher than before SRL introduction and after its withdrawal. Decreases in Hb correlated with increases in proinflammatory cytokine levels in a linear regression model. Unchanged serum IL10 levels measured at the nadir of anemia were discordant with the inflammatory state.. Late introduction of SRL may induce anemia and correlates with biochemical evidence of a chronic inflammatory state possibly due to defective IL10-dependent inflammatory autoregulation.

    Topics: Adult; Anemia; Chronic Disease; Female; Hemoglobins; Homeostasis; Humans; Immunosuppressive Agents; Inflammation; Interleukin-10; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Sirolimus; Syndrome; Time Factors

2005
Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
    Clinical nephrology, 2003, Volume: 59, Issue:3

    Posterior Leukoencephalopathy Syndrome (PLES) is a rare but serious neurological condition with many aetiologies. In the era of organ transplantation there have been sporadic reports of calcineurin-inhibitor associated PLES. We describe a case, with subsequent uneventful retransplantation using sirolimus.

    Topics: Brain Diseases; Calcineurin Inhibitors; Cyclosporine; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Magnetic Resonance Imaging; Male; Reoperation; Sirolimus; Syndrome; Tacrolimus

2003
In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A.
    Blood, 1996, May-01, Volume: 87, Issue:9

    Rapamycin (RAPA) has been shown to be a highly effective means of reducing the lethality of graft-versus-host disease (GVHD) in B10.BR recipients of allogeneic C57BL/6 donor cells. RAPA-treated mice had no clinical (e.g., weight loss, diarrhea, lethargy) or histologic evidence of classical acute or chronic GVHD but did develop a clinical-pathological syndrome consisting of ulcerative dermatitis, bile duct proliferation, and a nondestructive peribronchiolar pulmonary infiltration. Because RAPA was found to interfere with the deletion of self-reactive T cells, we wondered whether the RAPA-induced syndrome was related to failed negative selection or altered alloreactivity. We now show that the RAPA-induced syndrome is due to effects on mature, donor-derived alloreactive T cells. By titering the number of T cells infused we were able to vary the syndrome incidence. In contrast to the syndrome seen after cyclosporin A (CsA) administration, the RAPA syndrome did not require an intact thymus and the disease could not be adoptively transferred. The addition of CsA (which blocks T-cell cytokine production) to RAPA (which blocks T-cell cytokine response) prevented the generation of this syndrome, suggesting that the tissue manifestations seen in RAPA only treated recipients were caused by cytokine production and release. RAPA also caused this alloimmune syndrome in recipients of minor histocompatibility antigen disparate donor cells, showing that the RAPA effects were not restricted to a single donor-recipient strain combination or to instances in which the donor and recipient were fully major histocompatibility complex disparate. We conclude that RAPA is a highly effective means of preventing murine acute GVHD, and that when combined with CsA, warrants consideration for human investigations.

    Topics: Animals; Autoimmunity; Cyclosporine; Cytokines; Graft vs Host Disease; Immunosuppressive Agents; Mice; Polyenes; Sirolimus; Syndrome; T-Lymphocytes

1996